Clinical Trials Browser

Completed × Carcinoma, Transitional Cell × Paclitaxel × Clear all

Carcinoma, Transitional Cell

NCT02983045 2023-03-13

PIVOT-02

BreastDermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02581982 2023-01-10

Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer

Phase 2 Completed

27 enrolled 11 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02109328 2019-04-11

Alisertib in Chemotherapy-pretreated Urothelial Cancer

Phase 2 Completed

22 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00683059 2016-10-17

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

Phase 2 Completed

48 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT00154687 2007-07-31

Weekly TP-HDFL in the Treatment of Advanced TCC

Phase 2 Completed

40 enrolled

Genitourinary

Carcinoma, Transitional Cell

Clinical Trials

ICRA

PIVOT-02

Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer

Alisertib in Chemotherapy-pretreated Urothelial Cancer

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

Weekly TP-HDFL in the Treatment of Advanced TCC